
Sanofi licences vaccine against bacterial sepsis
Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive E. coli...

Antiverse and GlobalBio Inc. extend collaboration
AI specialist Antiverse Ltd (Cardiff, UK) and antobody engeeniering expert GlobalBio, Inc. (New York, USA) will be extending their collaboration to...

BioInnovation Institute Boosts Six Life Science Companies
The Venture House initiative aims at propelling former Venture Lab participants into the next phase of their development. “These six companies have...

$30m for genetic medicine advancements
Eligo Bioscience SA has secured $30m in a series B funding round led by Sanofi Ventures. The funding includes support from new investor Bpifrance, a...

Cellectis and AstraZeneca in US$2.2bn deal
Under the co-development agreement, that includes a US$80m equity investment and an option for a further equity investment of US$140m by AstraZeneca...

ViaNautis Bio Ltd closes US$25m Series A financing
The US$25m round of cambridge-based ViaNautis Bio Ltd, founded in 2018 as SomaServe, was led 4BIO Capital, BGF (both UK), and UCB Ventures (UK, US,...

Oxford Biomedica acquires ABL Europe for €15m
Oxford Biomedica PLC, and Institut Mérieux have entered exclusive negotiations for the acquisition of ABL Europe Inc. This move is set to solidify...